Aurinia Pharmaceuticals Inc. (AUPH) News
Follow Aurinia Pharmaceuticals Inc. (AUPH) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Aurinia Reports Fiscal Q3 Profit Growth of 35.42%
Aurinia reported fiscal 2026 third-quarter profit attributable to shareholders up 35.42% year over year, with basic EPS of 0.78 dollars.
EQUITY | Nov 02, 2026, 10:18 AM UTC
M
Aurinia says Teva generic voclosporin may launch after 2036
Aurinia Pharmaceuticals says Teva may launch a generic version of voclosporin in the U.S. no earlier than December 7, 2036, while patent litigation continues in New Jersey.
REGULATION | Aug 19, 2026, 08:06 PM UTC
L
Aurinia settles U.S. patent litigation with Teva over voclosporin
Aurinia Pharmaceuticals says it has settled patent litigation with Teva over generic voclosporin in the U.S.
REGULATION | Aug 19, 2026, 08:05 PM UTC
L
Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $323.065M Est
Aurinia Pharmaceuticals (NASDAQ: AUPH ) affirms FY2026 sales outlook from $315.000 million-$325.000 million to $315.000 million-$325.000 million vs $323.065 million estimate.
EARNINGS | Aug 06, 2026, 12:41 PM UTC